Advertisement
BIIB or EBS or LGND
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 0 FA rating(s) are green whileEBS’s FA Score has 1 green FA rating(s), and LGND’s FA Score reflects 0 green FA rating(s).
- BIIB’s FA Score: 0 green, 5 red.
- EBS’s FA Score: 1 green, 4 red.
- LGND’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 5 TA indicator(s) are bullish while EBS’s TA Score has 5 bullish TA indicator(s), and LGND’s TA Score reflects 2 bullish TA indicator(s).
- BIIB’s TA Score: 5 bullish, 3 bearish.
- EBS’s TA Score: 5 bullish, 5 bearish.
- LGND’s TA Score: 2 bullish, 8 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +2.69% price change this week, while EBS (@Pharmaceuticals: Other) price change was +1.42% , and LGND (@Biotechnology) price fluctuated +0.70% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.77%. For the same industry, the average monthly price growth was +2.01%, and the average quarterly price growth was +3.03%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +72.11%. For the same industry, the average monthly price growth was +14.53%, and the average quarterly price growth was +64.76%.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.21%. For the same industry, the average monthly price growth was +5.01%, and the average quarterly price growth was -2.10%.
Reported Earning Dates
BIIB is expected to report earnings on Jul 23, 2025.
EBS is expected to report earnings on Aug 12, 2025.
LGND is expected to report earnings on Aug 11, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (+2.77% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Pharmaceuticals: Other (+72.11% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Biotechnology (+6.21% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BIIB | EBS | LGND | |
| Capitalization | 31.3B | 120M | 1.98B |
| EBITDA | 2.04B | -518.2M | -122.1M |
| Gain YTD | -13.785 | -32.950 | -4.480 |
| P/E Ratio | 26.95 | 17.73 | 46.19 |
| Revenue | 9.84B | 1.02B | 181M |
| Total Cash | 1.05B | 112M | 209M |
| Total Debt | 7.34B | 860M | 4.45M |
BIIB | EBS | LGND | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 70 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 54 Fair valued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 65 | |
SMR RATING 1..100 | 71 | 94 | 92 | |
PRICE GROWTH RATING 1..100 | 62 | 49 | 61 | |
P/E GROWTH RATING 1..100 | 96 | 11 | 91 | |
SEASONALITY SCORE 1..100 | n/a | 65 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EBS's Valuation (54) in the Biotechnology industry is in the same range as LGND (76) and is somewhat better than the same rating for BIIB (87). This means that EBS's stock grew similarly to LGND’s and somewhat faster than BIIB’s over the last 12 months.
LGND's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for EBS (100) and is somewhat better than the same rating for BIIB (100). This means that LGND's stock grew somewhat faster than EBS’s and somewhat faster than BIIB’s over the last 12 months.
BIIB's SMR Rating (71) in the Biotechnology industry is in the same range as LGND (92) and is in the same range as EBS (94). This means that BIIB's stock grew similarly to LGND’s and similarly to EBS’s over the last 12 months.
EBS's Price Growth Rating (49) in the Biotechnology industry is in the same range as LGND (61) and is in the same range as BIIB (62). This means that EBS's stock grew similarly to LGND’s and similarly to BIIB’s over the last 12 months.
EBS's P/E Growth Rating (11) in the Biotechnology industry is significantly better than the same rating for LGND (91) and is significantly better than the same rating for BIIB (96). This means that EBS's stock grew significantly faster than LGND’s and significantly faster than BIIB’s over the last 12 months.
| BIIB | EBS | LGND | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 84% | N/A |
| Stochastic ODDS (%) | 1 day ago 69% | 1 day ago 72% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 61% | 1 day ago 86% | 1 day ago 82% |
| MACD ODDS (%) | N/A | 1 day ago 84% | 1 day ago 84% |
| TrendWeek ODDS (%) | 1 day ago 55% | 1 day ago 76% | 1 day ago 73% |
| TrendMonth ODDS (%) | 1 day ago 55% | 1 day ago 76% | 1 day ago 71% |
| Advances ODDS (%) | 1 day ago 54% | 16 days ago 76% | 6 days ago 72% |
| Declines ODDS (%) | 13 days ago 70% | 3 days ago 89% | 14 days ago 75% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 88% | 6 days ago 77% |
| Aroon ODDS (%) | 1 day ago 38% | 1 day ago 85% | 1 day ago 72% |
Advertisement
BIIB and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | +0.53% | ||
| AMGN - BIIB | 52% Loosely correlated | +0.38% | ||
| PFE - BIIB | 49% Loosely correlated | -0.47% | ||
| NVS - BIIB | 47% Loosely correlated | -0.65% | ||
| SNY - BIIB | 43% Loosely correlated | N/A | ||
| AZN - BIIB | 40% Loosely correlated | -0.15% | ||
More | ||||